公开(公告)号：US11034991B2

公开(公告)日：2021-06-15

申请号：US16085024

申请日：2017-03-16

Applicant: Oryzon Genomics S.A.

Inventor： Elena Carceller González ,  Tamara Maes ,  Cristina Mascaro Crusat ,  Alberto Ortega Muñoz

IPC: G01N33/50 ,  C12Q1/26 ,  C07D495/04 ,  G01N33/58

Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.

公开(公告)号：US20150232436A1

公开(公告)日：2015-08-20

申请号：US14184745

申请日：2014-02-20

Applicant: Oryzon Genomics S.A.

Inventor： Jonathan Alleman Baker ,  Julio Castro Palomino ,  Matthew Colin Thor Fyfe ,  Tamara Maes ,  Marc Martinell Pedemonte

IPC: C07D295/195 ,  A61K31/164 ,  A61K31/495 ,  C07D213/38 ,  A61K31/4418 ,  A61K45/06 ,  A61K31/40 ,  C07C215/64 ,  A61K31/135 ,  C07C311/32 ,  A61K31/18 ,  C07C237/20 ,  C07D207/14

CPC classification number: C07D295/195 ,  A61K31/00 ,  A61K31/131 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/164 ,  A61K31/18 ,  A61K31/40 ,  A61K31/4418 ,  A61K31/495 ,  A61K45/06 ,  C07D207/14 ,  C07D213/38

Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

Abstract translation: 本发明涉及用于治疗或预防与骨髓增生性疾病相关的疾病和病症的方法和组合物。 特别地，本发明涉及用于治疗或预防费城染色体阴性骨髓增生性疾病的LSD1抑制剂。

公开(公告)号：US12195783B2

公开(公告)日：2025-01-14

申请号：US17644604

申请日：2021-12-16

Applicant: Oryzon Genomics S.A.

Inventor： Elena Carceller González ,  Tamara Maes ,  Cristina Mascaro Crusat ,  Alberto Ortega Muñoz

IPC: G01N33/58 ,  C07D495/04 ,  C12Q1/26

Abstract: The invention relates to methods to determine KDM1A target engagement and chemoprobes useful therefor. In particular, the invention relates to non-peptidic KDM1A chemoprobes carrying a tag or label that can be used to assess KDM1A target engagement in cells and tissues. These chemoprobes can also be used to identify KDM1A interacting factors and analyze expression levels of KDM1A.

公开(公告)号：US09908859B2

公开(公告)日：2018-03-06

申请号：US14184745

申请日：2014-02-20

Applicant: Oryzon Genomics S.A.

Inventor： Jonathan Alleman Baker ,  Julio Castro Palomino ,  Matthew Colin Thor Fyfe ,  Tamara Maes ,  Marc Martinell Pedemonte

IPC: A61K31/135 ,  A01N33/02 ,  C07D295/195 ,  A61K31/164 ,  A61K31/495 ,  C07D213/38 ,  A61K31/4418 ,  C07D207/14 ,  A61K31/40 ,  A61K31/18 ,  A61K45/06 ,  A61K31/131 ,  A61K31/138 ,  A61K31/15

CPC classification number: C07D295/195 ,  A61K31/00 ,  A61K31/131 ,  A61K31/135 ,  A61K31/138 ,  A61K31/15 ,  A61K31/164 ,  A61K31/18 ,  A61K31/40 ,  A61K31/4418 ,  A61K31/495 ,  A61K45/06 ,  C07D207/14 ,  C07D213/38

Abstract: The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

公开(公告)号：US10780081B2

公开(公告)日：2020-09-22

申请号：US15741871

申请日：2017-06-09

Applicant: ORYZON GENOMICS, S.A.

Inventor： Tamara Maes ,  Cristina Mascarò Crusat ,  David Rotllant Pozo

IPC: A61K31/4245 ,  A61P25/28 ,  A61K31/42

Abstract: Provided herein are methods for treating multiple sclerosis using (−) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

公开(公告)号：US11013698B2

公开(公告)日：2021-05-25

申请号：US16084683

申请日：2017-03-13

Applicant: Oryzon Genomics S.A.

Inventor： Filippo Ciceri ,  Serena Lunardi ,  Tamara Maes ,  Cristina Mascaro Crusat ,  Inigo Tirapu Fernandez De La Cuesta

IPC: A61K31/05 ,  A61K31/12 ,  A61P35/02 ,  A61K31/135 ,  A61K31/17 ,  A61K31/203 ,  A61K31/282 ,  A61K31/015 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K31/19 ,  A61P35/00 ,  A61K31/496 ,  A61K33/36 ,  A61K31/64

Abstract: The instant invention relates to combinations of the compound of formula (I) or pharmaceutically acceptable salts thereof with other active pharmaceutical ingredients pharmaceutical compositions comprising them, and their use as medicaments, particularly for the treatment of hematological malignancies.

公开(公告)号：US10265279B2

公开(公告)日：2019-04-23

申请号：US15458640

申请日：2017-03-14

Applicant: ORYZON GENOMICS, S.A.

Inventor： Mark D. Demario ,  Tamara Maes ,  William E. Pierceall ,  Fiona Mack ,  Serena Lunardi

IPC: A61K31/135 ,  A61K31/55 ,  A61K31/551 ,  A61K31/4402 ,  A61K31/47 ,  A61K31/52 ,  A61K31/404 ,  A61K31/635 ,  A61K31/167 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/4745 ,  A61K31/12 ,  A61K31/19 ,  A61K31/282 ,  A61K31/337 ,  A61K31/4045 ,  A61K31/475 ,  A61K31/495 ,  A61K31/519 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068

Abstract: The instant invention relates to therapeutic combinations of LSD1 inhibitors and one or more other active pharmaceutical ingredient(s) or pharmaceutically acceptable salts thereof. The combinations are particularly useful for treating neoplastic diseases, such as cancer, particularly small cell lung cancer (SCLC).